

Innovative home dialysis therapies to support Japan's growing needs

17 September 2021 | News

Fresenius Medical Care partners with JMS to advance home dialysis treatment in Japan



German firm Fresenius Medical Care has announced a strategic distribution partnership with JMS Co. Ltd, a provider of medical devices and pharmaceuticals, in Japan.

Under the agreement, JMS Co. Ltd. will distribute Fresenius Medical Care's innovative home dialysis therapies in the Japanese market, providing patients with a wider range of dialysis choices to suit their lifestyle, enhance their wellbeing, and to help address the home healthcare needs of Japan's aging population

These systems, which have US Federal Drug Authority (FDA) and European CE Mark approvals, are used widely in other developed countries.

Japan has what is known as a 'super-aging society', with the largest elderly population in the world. By 2035, it is projected that 33 per cent of the total population will be aged 65 and over. Alongside this accelerated aging, the number of people requiring dialysis in Japan continues to grow each year.

"Fresenius Medical Care is committed to improving patients' quality of life through our expertise in chronic kidney disease management", said Harry de Wit, CEO & President of Fresenius Medical Care Asia Pacific. "Through providing various treatments options to healthcare professionals and patients, we aim to deliver on our vision – to create a future worth living, for patients, worldwide, every day".